High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.
about
Essential thrombocythemiaThe Role of Reactive Oxygen Species in Myelofibrosis and Related NeoplasmsMyeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patientsCIViC databaseThe treatment of polycythaemia vera: an update in the JAK2 eraEmerging drugs for myelofibrosis.2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and TThe role of HLA-G in immunity and hematopoiesis.Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cellsInterferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells.Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cellsExperience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patientsUpdate on JAK2 Inhibitors in Myeloproliferative NeoplasmDepletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia veraPegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia veraMolecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2aClinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study.Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090Anagrelide: 20 years later.Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.Advances in molecular diagnostics of myeloproliferative disorders.The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine.Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms.Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera.Bedside to bench: interfering with leukemic stem cells.Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.
P2860
Q21202968-D59E093A-712B-4F70-BDBE-5FC572FC9B63Q26779929-3F3D0F40-3900-48CB-A9B3-06FCDF4E7898Q26799388-A6DD9B31-A20D-4FE9-9649-C58DC4794C0EQ27612411-315C783A-8D9B-4C9B-B749-CB068F8DF815Q28212560-FD111CBA-0A5A-446E-B716-402748634C2AQ33404574-C4490D3E-3880-4E25-8A58-8D31064B9761Q33572605-F8E78BE8-9E8F-4D7C-97A4-B946BDDB6F49Q34024865-1670D2C0-778A-47C5-9212-51E9885679F0Q34360366-77C261AE-039F-4802-9223-3BC6B05EE8B3Q34949540-A2E784B2-D658-428F-838C-418EDC7F8AEFQ35743852-57664643-B7FA-4838-886C-69B772E559D1Q35944657-2A3A214D-879D-4FBF-BE0A-72FDBB3EFE9AQ36119271-A5035635-01D2-4D27-B3AB-4C4170E31042Q36169641-D8666F28-7BB6-45C0-8521-8C03533C56E8Q36169783-A04CE0D1-1F61-4B6E-91ED-C5E499333F82Q36311347-74339E98-A490-4450-8C52-8C0786A9B8FAQ36318162-3A034CC0-4C90-43D3-8C49-BE8B4EA87BCCQ36366962-B846568C-FADD-4F30-947B-78C139ED380BQ36612569-AE04EC14-B16D-404C-8B4D-DD6EB0E75718Q36814639-B767E383-E78E-47AA-9B46-EF8C78915A17Q36938773-F0FFC9D9-7665-4F3D-B854-46DEC7F5A856Q37083947-2105EFB7-BBFA-4D5C-8BCB-D042609B616BQ37170349-8B69D454-42D9-4149-A401-C4F83A5FB4ADQ37207792-C64CC4CA-AB18-4183-82A1-6F74258AE8C7Q37250169-381A41F4-BEEA-4A2C-A9CC-73FC608FEDB6Q37357291-B98F7838-C62C-41A6-8B97-ED3F59BBC259Q37705374-7A78023D-31BB-494F-90BA-28B665753575Q37955231-ED1200CC-C880-452F-B106-09DAC7F15870Q38028927-33629E30-4F5E-40F3-A4BD-E16016B53698Q38089228-60BD9D80-6A8B-4807-8586-65FD08EAF63EQ38239580-4ED35F72-77B4-4B06-A8CA-DB7A23E47622Q38909050-189C2411-FAE5-4112-8503-1D334F134F4EQ39691088-16B7E927-D808-4554-9317-5F7D3192DB04Q39918869-4FCEF947-F88C-4C98-8D5F-0AB1856B2615Q40039592-7A7C3199-485B-4721-BCA2-938CBEFFC7D4Q40297835-003A2762-E8CD-426F-9AB3-AFCD82B113A6Q40356455-BCE47A4A-4B14-4D7B-8C0A-0B1C9A5B85DFQ40959669-AB7ADEF9-075F-4AE3-B6F6-455964205835Q41463650-2076AA3F-9F17-4B56-9153-58935C217538Q41765680-7E9A5B8D-72CB-4023-B92E-55709B00A169
P2860
High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
High molecular response rate o ...... pegylated interferon alpha-2a.
@ast
High molecular response rate o ...... pegylated interferon alpha-2a.
@en
High molecular response rate o ...... pegylated interferon alpha-2a.
@nl
type
label
High molecular response rate o ...... pegylated interferon alpha-2a.
@ast
High molecular response rate o ...... pegylated interferon alpha-2a.
@en
High molecular response rate o ...... pegylated interferon alpha-2a.
@nl
prefLabel
High molecular response rate o ...... pegylated interferon alpha-2a.
@ast
High molecular response rate o ...... pegylated interferon alpha-2a.
@en
High molecular response rate o ...... pegylated interferon alpha-2a.
@nl
P2093
P50
P3181
P1433
P1476
High molecular response rate o ...... pegylated interferon alpha-2a.
@en
P2093
Gerald Massonnet
Jean-Didier Rain
Jean-François Bernard
Jean-Luc Dutel
Kamel Ghomari
Lina Abdelkader-Aljassem
Marie-Jose Grange
Marie-Laurence Menot
Nathalie Cambier
Nathalie Parquet
P304
P3181
P356
10.1182/BLOOD-2006-03-009860
P407
P50
P577
2006-09-15T00:00:00Z